Skip to main content
  • Home
  • Library
  • Read
    • Popular
    • Charts
    • Browse
    • Categories
    • Wikis
    • Glossary
  • Request
  • Activity
  • Leaderboard
  • Help
Our Apps
  • DaoSearch
  • Narratorr
Social
  • Discord
  • Patreon

Recaps

I Can Extract Side Effects
VolumesArcsSummaries

Arc 2Sanqing’s Breakthrough

Wei Kang built Sanqing Pharmaceutical through overseas licensing, new business ventures, and the fight to bring its anti-cancer drug to patients despite corporate and regulatory obstruction. After the drug won public attention and approval, Wei Kang left the arc negotiating an affordable domestic price with medical insurance officials.

  • Wei Kang signed a $3 billion overseas licensing agreement with Pfizer and directed Sanqing to expand production, research, and its future product lines.
  • Sheng Changya warned Wei Kang that Shiseido might acquire the Whitening Drug formula to eliminate a competitor, so Wei Kang rejected Shiseido and Procter & Gamble’s offers and asked Sheng to build a domestic cosmetics brand.
  • Wei Kang developed liver-protection capsules from an abandoned formula and planned new health supplement, cosmetics, and pharmaceutical businesses as Pfizer transferred its initial payment.
  • Jian Guohua recommended Sanqing’s anti-cancer drug to Qi Zhengyang’s family, and the drug stabilized Qi after surgery revealed his cancer had spread to his brain.
  • Merck obstructed the drug’s FDA application, but Qi publicly credited Sanqing with curing his cancer, and Mabus’s campaign led to FDA head Josen’s arrest.
  • Wei Kang announced that Sanqing’s drug had been approved and would launch in China, while Li Senqiang exposed He Shan’s false accusations about Sanqing’s treatment of overseas patients.
  • Wei Kang told the medical insurance negotiation team that Sanqing would price its drug below Keytruda, then offered caps of 200,000 yuan for employee insurance and 150,000 yuan for resident insurance.
  • Chen Linghui accepted Wei Kang’s proposed prices, and the teams began discussing the procurement plan as the hall applauded.
Chapters 26–50 Vol. 1 Read

Ch. 26A Net Worth of Ten Billion, the Largest Overseas Licensing Contract in History

Wei Kang signed a $3 billion overseas licensing agreement with Pfizer for Sanqing Pharmaceutical’s anticancer drug, making him an instant tycoon. The deal left Sanqing with a large upfront payment and further funds dependent on clinical and regulatory milestones.

  • Sanqing Pharmaceutical sold discarded drug formulas bundled by domestic and multinational companies, filling Wei Kang’s warehouse with formulas.
  • Wei Kang and Pfizer Inc.’s chief executive signed the overseas licensing agreement at a ceremony attended by municipal leaders and reporters.
  • Gao Tuyu praised Wei Kang, offered local land and support, and urged him to keep Sanqing Pharmaceutical’s headquarters in Kun City.
  • Wei Kang accepted Pfizer’s payment terms: $500 million upfront and $2.5 billion after registration approval and the start of sales, with repayment required if serious adverse reactions blocked approval.
  • Reporters crowded around Wei Kang with questions, and he wrote down the name of the journalist who asked how his parents’ deaths had affected him.
Read chapter

Ch. 27Business Adjustments, An Olive Branch from a Cosmetics Group

Wei Kang planned Sanqing Pharmaceutical’s expansion after its deal with Pfizer, including replacing old production equipment, building an R&D center, and sorting abandoned drug formulas. As Sanqing’s new drug drew widespread attention, inquiries about the Whitening Drug arrived from three international cosmetics companies.

  • Wei Kang announced that Sanqing would phase out low-profit generics and devote its production lines to the anti-cancer drug once it received approval.
  • Wei Kang ordered new automated production lines, a laboratory information system, an R&D center, and a search for nearby land for a future production base.
  • Wei Kang told Li Zhong to have the research team categorize more than two hundred sets of abandoned drug-development materials.
  • Media coverage made Sanqing famous, and Wei Kang posted on Langbo denying that hard work had driven his success.
  • Oulaiya Group, Shiseido Group, and Procter & Gamble Company sent inquiries about the Whitening Drug formula.
Read chapter

Ch. 28Oulaiya's Proposal

Wei Kang rejected Oulaiya’s low offer to buy Three Purities’ Whitening Drug formula, but Sheng Changya proposed a licensing or supply partnership that he agreed to discuss. As Sheng and Zhou Yuli left, Zhou warned her that Oulaiya’s management would reject the cooperation and that her efforts would be in vain.

  • Wei Kang reviewed Zhou Yuli’s acquisition proposal and rejected its eight-figure price as far too low.
  • Sheng Changya intervened with two alternatives: licensing the formula for an annual fee or supplying Oulaiya with its active ingredient.
  • Wei Kang agreed to continue discussions if Oulaiya considered one of Sheng’s cooperation plans, and Zhou said she would report them to the company.
  • After the meeting, Zhou told Sheng that she supported her proposal but believed Oulaiya’s management would reject it.
Read chapter

Ch. 29Industry Secrets, Sheng Changya's Little Thoughts

Sheng Changya learned that Oulaiya never intended to partner with Three Purities and, after hearing how Shiseido handled acquired formulas, realized its interest might be a way to suppress competition. She decided to warn President Wei and asked how his negotiations with Shiseido were going.

  • Zhou Yuli told Sheng Changya that Oulaiya had abandoned the whitening formula and had sent an acquisition proposal only to test whether President Wei would sell it cheaply.
  • Sheng Changya felt disillusioned with her work, but a cup of Luckin Coffee sparked an idea about the formula’s future.
  • Sheng Changya messaged Lucy, who told her Shiseido had bought many technologies and formulas without using them.
  • Sheng Changya recalled how acquired domestic brands such as Little Nurse had disappeared and concluded that Shiseido might be buying formulas to eliminate potential competitors.
  • Sheng Changya sent President Wei a message asking how his negotiations with Shiseido were going.
Read chapter

Ch. 30Shiseido and Procter & Gamble's Plan

Wei Kang met with Shiseido and Procter & Gamble to consider partnerships for his whitening prescription, then weighed their proposals against Oulaiya’s weak offer. As he prepared to choose a company, Sheng Changya messaged him to ask how his meeting with Shiseido had gone.

  • Wei Kang met Shiseido brand director Koizumi Taijiro, who presented an acquisition offer and an exclusive licensing proposal backed by a detailed marketing plan and a preassembled development team.
  • Wei Kang told Koizumi Taijiro he would decide only after meeting Procter & Gamble, and Koizumi left with his assistant.
  • Procter & Gamble vice president Denek proposed a partnership to add the whitening product to the SKII brand, and Wei Kang said he would consider the competing offers.
  • Wei Kang leaned toward Shiseido as he reviewed its and Procter & Gamble’s proposals, then received a WeChat message from Oulaiya product manager Sheng Changya asking how his Shiseido meeting had gone.
Read chapter

Ch. 31All Three Families Fell Apart

Sheng Changya warned Wei Kang that Shiseido intended to acquire the Whitening Drug formula and bury it, prompting him to reject Koizumi Taijiro’s proposal. Wei Kang then chose Procter & Gamble, but Denek lowered the offer to an 80-million one-time buyout after the other bidders withdrew.

  • Sheng Changya told Wei Kang that Shiseido had a history of acquiring companies and technologies without launching their products, and warned that it might want the Whitening Drug formula only to eliminate a competitor.
  • Wei Kang tested Koizumi Taijiro by demanding that Shiseido launch a new product line within six months, and Koizumi could not agree to the condition.
  • Wei Kang accused Koizumi of deceiving him and ended the call, while Koizumi told Denek that the deal with Three Purities had fallen through and Oulaiya had withdrawn.
  • Wei Kang decided to cooperate with Procter & Gamble and called Denek, who said the offer had to change because his company was now the only bidder.
  • Denek offered an 80-million one-time buyout as his final price, and Wei Kang responded with a sharp smack.
Read chapter

Ch. 32Sheng Changya's Ambition, Domestic Independent Brands

After rejecting three foreign companies, Wei Kang considered entering the cosmetics industry and asked Sheng Changya for advice. Sheng Changya urged him to build an independent domestic brand around the Whitening Drug and offered to lead the effort.

  • Wei Kang grew furious at Oulaiya, Shiseido, and Procter & Gamble, then resolved to support a domestic cosmetics company and defeat the foreign giants.
  • Wei Kang realized he knew little about the domestic cosmetics industry and called Sheng Changya for advice.
  • Wei Kang told Sheng Changya that negotiations with the foreign companies had failed and asked her to recommend domestic partners or share a better plan.
  • Sheng Changya argued that the Whitening Drug could anchor a successful independent domestic cosmetics brand.
  • When Wei Kang said he lacked people, Sheng Changya recommended herself to build the brand.
Read chapter

Ch. 33This Side Effect is Truly Wonderful

Sheng Changya secured a chance to lead Wei Kang’s cosmetics project by promising to deliver a feasibility report and product plan. Meanwhile, Wei Kang searched abandoned formulas for a marketable health supplement and found an antacid formula with a promising alcohol-breakdown side effect.

  • Wei Kang told Sheng Changya to prove her abilities with a feasibility report in three days and a product development plan within a week, promising to invest and entrust her with company affairs if he was satisfied.
  • Sheng Changya accepted the challenge, arranged a week of leave and work handover, then began writing the feasibility report.
  • Wei Kang reviewed abandoned pharmaceutical formulas while seeking a health supplement that could quickly reach the market.
  • Wei Kang rejected an antihypertensive formula because of its kidney damage, then found an antacid formula whose mild toxicity and alcohol-breakdown side effect excited him.
Read chapter

Ch. 34The Strongest Hangover Cure is Born

Wei Kang extracted a side effect that accelerated alcohol metabolism and created a powerful liver-protection supplement. He planned to add ingredients that kept drinkers alert and a warning against binge drinking before moving toward production.

  • Wei Kang learned that reaching Lv10 would unlock a lottery draw costing 1,000 points, then spent 100 points extracting a side effect that stimulated enzymes responsible for alcohol metabolism.
  • The system produced a prescription that greatly increased the activity of alcohol- and acetaldehyde-metabolizing enzymes, and Wei Kang celebrated its potential as a hangover remedy.
  • Wei Kang researched liver-protection supplements and combined their ingredients with the system’s formula to create reinforced liver-protection capsules.
  • Wei Kang worried that the supplement might encourage binge drinking, so he decided to add ingredients that would keep users alert and a prominent warning against excessive drinking.
Read chapter

Ch. 35500 Million USD Arrives, Entering the Health Product Market

Wei Kang prepared to launch Sanqing’s hangover supplement and planned how to build a sales operation while awaiting Pfizer’s payment. After Jian Lianyun urged him to focus on lifesaving drugs, she called her father to ask about a matter they had discussed.

  • Wei Kang discussed sales with Sun Chengren, who recommended outsourcing a specialist team or acquiring a supplement company; Wei chose to outsource first and consider an acquisition once Pfizer’s funds arrived.
  • Wei Kang told Sun Chengren that Sanqing aimed to establish health supplement, cosmetics, and pharmaceutical subsidiaries, then received Andre’s news that Pfizer had transferred its initial payment and was pursuing FDA approval.
  • Wei Kang realized Sanqing needed more products and resolved to search discarded prescriptions for new drugs.
  • Jian Lianyun reminded Wei Kang to attend a follow-up examination and advised him to devote his research to medicines that treated diseases rather than supplements.
  • After ending the call, Jian Lianyun phoned her father to ask how their previously discussed matter had gone.
Read chapter

Ch. 36Father's Love is Like a Mountain

Jian Lianyun urged her father, Jian Guohua, to recommend Wei Kang’s anticancer drug to the critically ill Academician Qi, while Jian Guohua teased her about her admiration for Wei Kang. After advising her to be gentler with him, Jian Guohua set out for the special care ward to discuss the drug with Qi.

  • Jian Guohua told Jian Lianyun that he had gathered information on Wei Kang’s anticancer drug and was preparing to recommend it to Academician Qi.
  • Jian Lianyun praised Wei Kang’s research and complained that he focused too much on making money, while Jian Guohua teased her about liking him.
  • Jian Guohua explained Sanqing Pharmaceutical’s financial difficulties and advised Jian Lianyun to be more understanding and tactful with Wei Kang.
  • Jian Lianyun agreed to change how she spoke to Wei Kang, then urged Jian Guohua to handle Academician Qi’s case quickly.
  • Jian Guohua took documents and walked toward Ruiji Hospital’s special care ward to see Qi.
Read chapter

Ch. 37Pancreatic Cancer, King of All Cancers

Jian Guohua told Qi Yetting and his wife that Academician Qi Zhengyang’s pancreatic cancer was worsening and that surgery was risky, while recommending an unapproved domestic anti-cancer drug they rejected. The family chose to postpone surgery until after Qi Zhengyang attended his Medal of the Republic ceremony in two weeks, and Jian Guohua agreed to help manage his pain in the meantime.

  • Jian Guohua examined Qi Zhengyang and found that his symptoms and scans showed the pancreatic cancer was progressing.
  • Jian Guohua warned Qi Yetting and his wife that surgery was dangerous but that delaying treatment could allow the cancer to spread further.
  • Jian Guohua proposed a Broad-Spectrum Anti-Cancer Drug still in Phase Three trials, but the family rejected it as experimental and unreliable.
  • Qi Yetting explained that Qi Zhengyang wanted to attend his Medal of the Republic presentation ceremony before undergoing surgery.
  • Jian Guohua agreed to prescribe pain relief and other medication to help Qi Zhengyang hold on until the ceremony.
Read chapter

Ch. 38Academician Qi Rescued, FDA Thwarted

After Academician Qi's cancer metastasized to his brain and left him unconscious, Jian Guohua arranged for him to receive the Three Purities anticancer drug, which stabilized his condition. Meanwhile, Josen stalled FDA approval of the drug under pressure from Merck, and Andre told Wei Kang the application would be delayed.

  • Three days after Jian Guohua failed to persuade Qi Yetting's family to use the drug, Academician Qi's condition deteriorated, and Jian Guohua operated on him.
  • After the surgery, doctors discovered that Academician Qi's cancer had spread to his brain, so his family begged Jian Guohua to try the anticancer drug.
  • Jian Guohua obtained the family's consent, and Jian Lianyun brought the drug, which improved and then stabilized Academician Qi's vital signs.
  • Josen set aside Pfizer's drug application after Merck urged him to delay it, then rejected Andre's attempts to discuss the approval.
  • Andre concluded Merck and Roche were influencing Josen and called Wei Kang to warn him that FDA approval would be delayed.
Read chapter

Ch. 39"The Lancet" Oncology Treatment Paper Published

Wei Kang learned that Merck was obstructing the Sanqing Anti-Cancer Drug's overseas approval, so he focused on lowering its price for the domestic market. After Jian Lianyun confirmed he was cured, she shared that their clinical-trial paper had appeared in The Lancet Oncology and that Academician Qi was recovering; she said he would help expedite the drug's approval.

  • Andre told Wei Kang that the overseas launch was delayed at the FDA approval stage, and Wei Kang suspected Merck was behind the obstruction.
  • Wei Kang planned to compete with Keytruda in China by lowering the Sanqing Anti-Cancer Drug's price, while Sheng Changya began developing whitening products using outsourced production.
  • Wei Kang visited Kun City First People's Hospital for a follow-up examination, and Jian Lianyun confirmed that no cancer cells remained in his body.
  • Jian Lianyun told Wei Kang that her clinical-trial paper had been published in The Lancet Oncology and listed him as its second author.
  • Jian Lianyun reported that Academician Qi's pancreatic cancer had stabilized after treatment with the Sanqing Anti-Cancer Drug and that he intended to help speed its approval.
Read chapter

Ch. 40Thanking the Three Purities for Saving My Life

Wei Kang and Jian Lianyun shared dinner and watched Academician Qi Zhengyang publicly credit Sanqing Pharmaceutical’s anti-cancer drug with saving his life. The broadcast sent diners and online viewers into an uproar and left one man grieving that his father had died before the medicine became available.

  • Wei Kang and Jian Lianyun went to a nearby home-cooking restaurant and talked about Jian Lianyun’s career and family.
  • Jian Lianyun asked the restaurant proprietress to turn up the television when the news showed Academician Qi Zhengyang receiving the National Honor Medal.
  • Academician Qi said he had terminal pancreatic cancer but recovered after taking Sanqing Pharmaceutical’s New Anti-Cancer Drug, and he thanked the company for saving his life.
  • The diners reacted with surprise and discussed Sanqing’s medicine as news of Qi’s statement spread online.
  • A middle-aged man broke down, lamenting that his father had died before he could take the medicine.
Read chapter

Ch. 41Chapter 41

Wei Kang and Jian Lianyun watched Academician Qi praise Sanqing Pharmaceutical and its anti-cancer drug on television. After a diner mocked Wei Kang’s ambition to receive the Medal of the Republic, the man posted photos of him online, only for netizens to identify Wei Kang and ridicule the blogger.

  • Wei Kang and Jian Lianyun stayed at the restaurant to watch Academician Qi discuss his recovery from cancer and praise Sanqing Pharmaceutical on Focus Interview.
  • Inspired by Academician Qi’s medal, Wei Kang said he hoped to receive the Medal of the Republic one day, and Jian Lianyun cheered him on.
  • A skinny young man mocked Wei Kang’s ambition, so Jian Lianyun revealed that Wei Kang owned Sanqing Pharmaceutical and had invented the anti-cancer drug.
  • The young man photographed Wei Kang and posted a mocking account on Langbo, but netizens recognized Wei Kang and corrected him.
  • The young man realized his mistake, deleted the post, and left the restaurant in humiliation.
Read chapter

Ch. 42The Lure of Medals, Wei Kang's Ambition

Wei Kang watched Academician Qi credit the Sanqing Anti-Cancer Drug with restoring his health and aspired to receive the National Honor Medal himself. After a diner mocked him and posted his photo online, netizens recognized Wei Kang and exposed the blogger's mistake.

  • Wei Kang and Jian Lianyun stayed at the restaurant to watch Academician Qi describe his cancer treatment and recovery with the Sanqing Anti-Cancer Drug.
  • Wei Kang admired Academician Qi's medal and declared that he would receive the National Honor Medal too, while Jian Lianyun encouraged him.
  • A skinny young man mocked Wei Kang, and Jian Lianyun revealed that Wei Kang owned Sanqing Pharmaceutical and had invented the drug.
  • The young man posted mocking photos of Wei Kang on Langbo, but netizens recognized Wei Kang and ridiculed the blogger for failing to identify him.
  • The young man deleted his post, paid his bill, and left in embarrassment.
Read chapter

Ch. 43The Fury of Global Richest Man Mabus

Mabus learned that he had pancreatic cancer and refused surgery, demanding treatment with Sanqing’s anticancer drug. After discovering that the FDA had blocked the drug’s entry into Eagle Country, he blamed Josen and vowed to ruin him.

  • Mabus arrived at Mayo Clinic and berated Dr. James for failing to find his pancreatic cyst earlier.
  • Dr. James recommended surgery, but Mabus refused and showed him a report about Sanqing’s anticancer drug and Dr. Qi’s recovery.
  • Mabus ordered Dr. James to obtain the drug, but Dr. James learned from Pfizer’s representative that the FDA had delayed its clinical trial application.
  • Andre told Dr. James that Merck had pressured the FDA to suppress the drug because it threatened Keytruda, and that Josen was allied with Merck’s sponsor, Congressman Brown.
  • Mabus vowed to make Josen lose everything and insulted him.
Read chapter

Ch. 44FDA Needs a Change

FDA chief Josen discovered that a public protest against his rejection of a new anti-cancer drug had gathered outside his headquarters, while Mabus publicly accused him of corruption. After learning the drug might treat Mabus’s pancreatic cancer, Josen realized his political allies were abandoning him and feared losing his position and freedom.

  • Josen’s secretary told him to read the news, and he realized a growing protest outside FDA headquarters targeted his rejection of the New Anti-Cancer Drug.
  • Josen blamed Pfizer, but his secretary told him Mabus had named him in an angry Twitter post accusing him of abusing his authority and taking corrupt payments.
  • Josen learned that Mabus had pancreatic cancer and that the Eastern drug had reportedly cured a Nobel Prize in Physics winner with the same illness.
  • Josen called Congressman Brown and pleaded for help, promising to approve the drug and apologize to Mabus.
  • Congressman Brown refused to see Josen and told him Mabus wanted him removed, leaving Josen collapsed and afraid that his dealings would be exposed.
Read chapter

Ch. 45Sanqing Anti-Cancer Drug, When Will It Be Available?

Mabus praised Sanqing Anti-Cancer Drug after experiencing its benefits, while news of the FDA head’s arrest fueled excitement and demands for the drug’s domestic release. An overseas Chinese cancer patient then accused Sanqing of charging exorbitant prices and discriminating against Chinese patients, igniting a backlash online.

  • Mabus used Sanqing Anti-Cancer Drug at Mayo Clinic, praised its effectiveness, and asked his assistant to buy bottles of Sanqing’s hangover remedy.
  • Mabus posted that Sanqing’s drug had saved his pancreas, and fans celebrated his recovery while hoping the drug would become available.
  • News spread that FDA head Josen had been arrested for colluding with pharmaceutical companies and blocking Sanqing Anti-Cancer Drug, prompting claims that the FDA would expedite its approval.
  • Domestic netizens celebrated Sanqing’s influence and flooded Wei Kang’s Langbo with demands to know when the cancer drug would be released in China.
  • An overseas Chinese terminal cancer patient accused Sanqing of charging one million US dollars per month, rejecting Chinese clinical trial applicants, and leaving ordinary patients unable to afford treatment.
  • The patient’s accusations and posted medical records sparked an uproar across the internet.
Read chapter

Ch. 46The Truth Revealed, Accelerating the Listing

Li Senqiang took his father to Eagle Country for cancer treatment, but the Anderson Cancer Center recommended an exorbitantly priced drug made by Sanqing, prompting him to return to China. After learning the drug was approved and might be covered by medical insurance, he exposed He Shan for attacking it online, just as Wei Kang announced Sanqing’s imminent launch.

  • Li Senqiang brought his father to the Anderson Cancer Center, where doctors ordered costly tests and recommended a Sanqing-made drug priced far above conventional treatments.
  • Li Senqiang searched for Sanqing after returning to his apartment, learned about its anticancer drug, and took his parents back to China the next day.
  • Kun City First People's Hospital told Li Senqiang that the Sanqing Anti-Cancer Drug was approved for sale and that medical insurance negotiations were underway.
  • Li Senqiang recognized He Shan as the overseas Chinese accusing Sanqing of exploiting patients, then posted his treatment records and exposed He Shan’s background.
  • Netizens attacked He Shan, who deleted his Langbo account before the platform banned him for spreading false information.
  • Wei Kang addressed Li Senqiang online and announced that Sanqing had passed approval and would launch soon.
Read chapter

Ch. 47Domestic Pricing Captures Hearts

Wei Kang announced that the Sanqing Anti-Cancer Drug had received expedited approval and would be affordable domestically, while also entering the national medical insurance centralized procurement process. As the public and pharmaceutical industry awaited price negotiations in Kun City, Sanqing faced rising expectations about whether it could make the drug accessible.

  • Wei Kang announced that the Sanqing Anti-Cancer Drug would launch that day and that patients could arrange treatment at nearby Grade A Tertiary Hospitals.
  • Wei Kang said Sanqing would keep the domestic price affordable and revealed that the drug had entered the National Healthcare Security Administration’s centralized procurement catalog, with negotiations to be livestreamed.
  • Netizens praised Sanqing and Wei Kang, while critics questioned the promises and others demanded low prices for overseas patients; supporters defended Sanqing against the criticism.
  • Domestic pharmaceutical companies questioned Wei Kang’s plan to lower prices, then prepared to see how the negotiations affected their anti-cancer drug projects.
  • The Medical Insurance Centralized Procurement Negotiation Team arrived in Kun City.
Read chapter

Ch. 48The Medical Insurance Negotiation Team Arrives

Wei Kang welcomed Academician Qi and Chen Linghui as the Sanqing Anti-Cancer Drug medical insurance negotiations began under intense public attention. The teams took their seats, but the negotiations had not yet started when livestream viewers became distracted by Wei Kang’s appearance.

  • Netizens watched the Sanqing Anti-Cancer Drug negotiations livestream and hoped the talks would make the medicine affordable.
  • Wei Kang waited at Sanqing Pharmaceutical headquarters and warmly greeted Academician Qi when he arrived with the medical insurance team.
  • Academician Qi praised Sanqing’s drug and promised to support Wei Kang’s decisions, then introduced Chen Linghui as the negotiation team leader.
  • Wei Kang and Chen Linghui sat opposite each other with their teams, while Academician Qi took a seat beside Wei Kang.
  • Livestream viewers debated the negotiators’ bargaining skills, then focused on Wei Kang’s looks as the cameras gave him close-up shots.
Read chapter

Ch. 49This Price Is Really Too Low

At the National Medical Insurance negotiations, Chen Linghui pushed Wei Kang to offer a steep discount on Sanqing’s anti-cancer drug in exchange for a favorable reimbursement rate. Wei agreed the drug would cost less than Keytruda, but Chen’s proposed reimbursement caps left the room waiting to see whether he would accept.

  • Chen Linghui invoked Sanqing’s public promises and national responsibility to press Wei Kang for a major price concession, offering a higher reimbursement rate in return.
  • Wei Kang assured Chen that Sanqing would honor its word and price its anti-cancer drug below Keytruda.
  • Wei rejected pricing Sanqing’s independently developed drug like a generic, arguing that its value and overseas recognition warranted treatment as a new drug.
  • Chen cited national income and medical insurance limits, then proposed reimbursement caps of 200,000 yuan for resident insurance and 250,000 yuan for employee insurance.
  • The negotiators watched Wei Kang expectantly as Chen’s proposed caps appeared low compared with the drug’s efficacy and overseas price.
Read chapter

Ch. 50Never Heard Such an Outrageous Request

Wei Kang rejected the negotiating team’s proposed price for Sanqing’s anti-cancer drug as too high and offered lower prices for employee and resident medical insurance. Chen Linghui accepted Sanqing’s offer and moved the talks toward finalizing the centralized procurement plan.

  • The negotiating team proposed a price of just over 200,000, and livestream viewers reacted with astonishment.
  • Wei Kang said the proposed price was too high and urged Chen Linghui to lower it further.
  • Wei Kang offered a price capped at 200,000 for employee medical insurance and 150,000 for resident medical insurance, aiming to keep patients’ out-of-pocket costs under 100,000 after reimbursement.
  • Chen Linghui accepted Sanqing’s quoted prices and began discussing details of the procurement plan with Wei Kang.
  • The people in the hall applauded as the negotiations continued.
Read chapter
Arc 2 of 27
AboutStatsAPIChangelogStatusContactPrivacyTermsDMCA
© 2026 RandomTranslator·v3.26·RSS